<DOC>
	<DOC>NCT02876900</DOC>
	<brief_summary>This study is designed to evaluate efficacy and safety of HP-3070 compared with placebo transdermal patch in subjects diagnosed with schizophrenia.</brief_summary>
	<brief_title>Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia.</brief_title>
	<detailed_description>This is a Phase 3, randomized, double-blind, placebo-controlled, in-patient, safety, and efficacy study to evaluate HP-3070 for the treatment of schizophrenia. This study is designed to evaluate efficacy and safety of HP-3070 compared with placebo transdermal patch in subjects diagnosed with schizophrenia, who are in an acute exacerbation and to assess the impacts of covariates on asenapine exposure as delivered in a patch formulation, using a population-based approach.</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Asenapine</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>Current diagnosis of schizophrenia. Subject has PANSS total score â‰¥80, AND score of 4 or more in at least 2 of the following PANSS items at Screening and at Baseline: conceptual disorganization delusions; hallucinatory behavior; unusual thought content. Subjects must be able to wear a transdermal patch for 24 hours. Subject has been diagnosed with schizophrenia less than 6 months prior to Screening Visit. Subject has received within 90 days of Screening Visit: electroconvulsive therapy; transcranial magnetic stimulation; vagal nerve stimulation; or other brain stimulation treatments Subject has experienced acute depressive symptoms within 30 days prior to Screening Visit that requires treatment with an antidepressant, as determined by the Investigator. Currently taking clozapine for the treatment of schizophrenia. Has hypothyroidism or hyperthyroidism. Subject is currently being treated with insulin for diabetes. Subject has epilepsy or history of seizures. Positive urine pregnancy test.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>